The naive question first: what is CRISPR Therapeutics, and why does its name keep coming up in the gene-editing story? The short version, drawn from its own filings, is that it is the company that helped turn CRISPR from a Nobel-winning laboratory tool into an approved medicine — and then handed much of the steering to a partner.
The defining fact is Casgevy. CRISPR Therapeutics' third-quarter 2025 10-Q states that in 2023 Casgevy became the first-ever approved CRISPR-based gene-editing therapy in the world. Think of it like the first car off a brand-new kind of assembly line: the achievement is not just the product, it is proving the whole approach can reach patients. For sickle cell disease and beta thalassemia — inherited blood disorders — that is a genuine landmark.
The second defining fact is the partner. The company's 2025 annual report (10-K, filed February 12, 2026) lists among its risks that it collaborates with Vertex on its lead program Casgevy and that Vertex has significant control over the program. In plain terms, CRISPR Therapeutics co-invented the therapy but does not solely run it — Vertex holds the trademark, recurring across the company's 2026 10-Q and proxy filings, and significant control.
Why structure it that way? Because bringing a complex cell therapy to market — manufacturing edited cells, navigating regulators in multiple countries, building a commercial operation — is enormous. Partnering with a larger, cash-rich company like Vertex lets a younger biotech share that burden. The trade is control and economics for reach and resources, and the filing names the trade openly.
For a newcomer, the takeaway is balance. CRISPR Therapeutics is a real scientific pioneer with the first approved CRISPR therapy to its name, and it has a pipeline beyond Casgevy that its filings describe pursuing. But its single most important asset is governed by a collaboration in which the partner has the larger say — a fact you only learn by reading the disclosure, not the headlines celebrating the science.
The EdgarBeast evidence index makes a from-the-filings primer like this possible: the same milestone language and the same control-and-trademark caveats recur across the company's documents, so a reader can build an accurate picture from primary sources. CRISPR Therapeutics, in its own words, is a pioneer with a powerful partner at the wheel of its flagship.